ITI 214

Drug Profile

ITI 214

Alternative Names: IC-200214; ITI-214

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Intra-Cellular Therapies
  • Class Antiparkinsonians; Nootropics; Small molecules
  • Mechanism of Action Type 1 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cognition disorders

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cognition-disorders in Japan (PO, Liquid)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cognition-disorders in USA (PO, Liquid)
  • 21 Sep 2015 Takeda completes a phase I bioavailability trial in Cognition disorders in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top